Dr Reddy's launches Debiopharm's cancer drug Pamorelin LA in India

Independent Swiss biopharma firm Debiopharm Group announced on Friday that, on December 3, Dr. Reddy's Laboratories (NYSE: RDY), India’s second largest drugmaker, launched Pamorelin (triptorelin) LA in India for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer.

Under the terms of the agreement, financial terms of which were not disclosed, Dr Reddy's acquires exclusive marketing and sales rights for Pamorelin LA Depot in India. The product is exported in bulk from Debio Recherche Pharmaceutique to Dr Reddy's. Pamorelin LA will be made available primarily to urologists and oncologists across India.

“We recognise the need for prostate cancer treatment in India and are thrilled to have the opportunity to bring Pamorelin LA to Indian patients,” said Rolland-Yves Mauvernay, president and founder of Debiopharm Group, adding: 'This major step enables us to implement our strategy in one of the most important markets in Asia. This is only the logical continuation to a harmonious working relationship shared with Dr Reddy's over the years.”